Vaxcyte (PCVX) Current Leases (2019 - 2026)

Vaxcyte (PCVX) has 7 years of Current Leases data on file, last reported at $6.1 million in Q1 2026.

• On a quarterly basis, Current Leases fell 0.7% year-over-year to $6.1 million in Q1 2026; TTM through Mar 2026 was $6.1 million, a 0.7% decrease from a year earlier, with the FY2025 full-year figure at $6.1 million, up 3.96% from the prior year.
• Current Leases for Q1 2026 stood at $6.1 million, down from $6.1 million in the prior quarter.
• Over the last five years, Current Leases for PCVX reached as high as $9.6 million in Q3 2024 and fell as low as $5.8 million in Q3 2025.
• Historically, Current Leases has averaged $6.5 million across 5 years, with a median of $6.1 million in 2025.
• Across the five-year window, Current Leases jumped 948.29% in 2022 and plunged 40.12% in 2025, its largest moves.
• Year by year, Current Leases stood at $5.9 million in 2022, then gained by 20.36% to $7.1 million in 2023, then decreased by 17.18% to $5.9 million in 2024, then grew by 3.96% to $6.1 million in 2025, then retreated by 0.64% to $6.1 million in 2026.
• Per Business Quant data, the three most recent Current Leases figures were $6.1 million in Q1 2026, $6.1 million in Q4 2025, and $5.8 million in Q3 2025.